Oct 15
|
Zacks.com featured highlights include Grupo Supervielle, Emergent BioSolutions and Innodata
|
Oct 14
|
3 Stocks Poised for Better Returns With New Analyst Coverage
|
Oct 11
|
Emergent BioSolutions Inc. (EBS): A Standout Among Best Performing Cheap Stocks in 2024
|
Oct 9
|
Emergent BioSolutions Inc (EBS) Q2 2024 Earnings Call Highlights: Navigating Challenges and ...
|
Oct 9
|
Emergent to donate 20,000 Narcan doses to fight opioid overdoses, CEO says
|
Sep 26
|
Emergent BioSolutions Announces the Execution of Contract Options Valued at $67.4 Million to Procure Additional TEMBEXA® (brincidofovir) to Support National Preparedness Efforts
|
Sep 25
|
Emergent BioSolutions Confirms Approximately $400 million in Orders in 2024 & 2025 to Support Smallpox and Mpox Preparedness Efforts
|
Sep 24
|
Emergent BioSolutions Inc.'s (NYSE:EBS) institutional investors lost 16% last week but have benefitted from longer-term gains
|
Sep 4
|
Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors
|
Sep 3
|
Emergent BioSolutions Successfully Refinances Debt & Further Strengthens Financial Profile
|
Aug 30
|
EBS Stock Rises on FDA Nod for ACAM2000 in Mpox Indication
|
Aug 30
|
Emergent BioSolutions Stock Soars as FDA Approves Mpox Vaccine
|
Aug 30
|
This Biotech Stock Surges As WHO Health Emergency Stirs FDA Approval
|
Aug 30
|
Emergent BioSolutions Expands Ready to Rescue Initiative to Support Widespread Opioid Emergency Preparedness
|
Aug 30
|
Emergent gains FDA approval for ACAM2000 vaccine for Mpox
|
Aug 29
|
Emergent BioSolutions’ ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) Receives U.S. FDA Approval for Mpox Indication; Public Health Mpox Outbreak Continues Across Africa & Other Regions
|
Aug 26
|
Emergent to cut up to 70 roles at Lansing facility
|
Aug 7
|
Emergent BioSolutions (EBS) Q2 2024 Earnings Call Transcript
|
Aug 6
|
Emergent Biosolutions: Q2 Earnings Snapshot
|
Aug 6
|
Emergent BioSolutions Reports Second Quarter 2024 Financial Results
|